Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03798522
Other study ID # N-42-2018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2019
Est. completion date September 30, 2019

Study information

Verified date January 2020
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

bilateral continuous erector spinae plane blockade may represent a valuable alternatives to thoracіc epidurals analgaesіa in treatment of thoracic neuropathic pain.

There were 3 cases reported in 2017 suggested that the erector spinae plane block provides visceral abdominal analgesia in bariatric surgery and at end of the report they recommended further clinical investigation. The investigators hypothesіzed that performing the erector spinae plane (ESP) block at T7 would provide effective abdominal analgaesіa іn patients undergone laparoscopic bariatric surgery. The investigators aimed to compare the analgesic effect of erector spinae plane block and opioid based general anesthesia for laparoscopic bariatric surgeries.


Description:

The investigators hypothesized that, erector spinae plane block will provide good analgesia for patients undergoing laparoscopic bariatric surgery with less complication compared to opioid based general anesthesia. The visual analogue scale (VAS) will be explained clearly to all participants before conduction of anesthesia. All the drugs will be calculated according to the ideal body weight (IBW).A low-frequency (2-5 MHz) curved array ultrasound probe (Mindray®, China) will be used. In the 1st group: bilateral ultrasound-guided erector spinae plane block will be performed under complete aseptic conditions in the lateral position at T7 vertebrae and before induction of general anesthesia. An 8-cm echogenic 22-G block needle will be inserted in-plane. A total of 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will then be injected into the erector spinae plane. This procedure will be repeated on the contralateral side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine). In the 2nd group: the investigator will give intravenous nalbuphine in a dose of 2mg /kg according to ideal body weight after induction of general anesthesia. All participants will be given 1 gram of intravenous paracetamol (15 mg/Kg), together with 4 mg ondansetron 10 min prior to the end of surgery for postoperative nausea and vomiting prophylaxis.

Intraoperatively, any increase in heart rate and/or arterial blood pressure 10 min after intubation by more than 20% of baseline values in response to surgical stimulus or thereafter throughout the whole operation will be managed by intravenous administration of fentanyl 0.5 µg/Kg. VAS score will be assessed 30 min after extubation and when the VAS score exceeded 4/10, rescue analgesia in the form of IV nalbuphine 5 mg will be administered. Another dose of rescue analgesia can be given in the post anesthesia care unit (PACU) if the VAS still more than 4 after 60 min of extubation. If still high, Ketorolac 60 mg will be given by intravenous infusion.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date September 30, 2019
Est. primary completion date August 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Patient age >18 <60

- Obese patients 40? Body mass index(BMI) ?50

- Both sexes

- American Society of Anesthesiologists(ASA) physical status classes II and III

- Patients scheduled for laparoscopic bariatric surgery i.e. sleeve gastrectomy and/or Roux-en-Y gastric bypass (RYGB)surgeries

Exclusion Criteria:

- Refusal of regional block

- Patients with neurological, psychological disorders or those lacking cooperation

- Patients scheduled for concomitant laparoscopic cholecystectomy or paraumbilical hernia repair or those with history of previous bariatric surgery or obstructive sleep apnea

- Patients with anatomic abnormalities at site of injection, skin lesions or wounds at site of proposed needle insertion.

- Patients with bleeding disorders defined as (INR >2) and/ or (platelet count <100,000/µL)

- Patients with hepatic disease e.g. liver cell failure or hepatic malignancy or hepatic enlargement.

- Patients who are allergic to amide local anesthetics.

- Cases converted to open surgery will also be excluded from the study

Study Design


Intervention

Procedure:
bilateral ultrasound guided erector spinae plane block
ESPB on both sides at T7 before GA
Drug:
Nalbuphine
in nalbuphine for analgesia after GA

Locations

Country Name City State
Egypt Hany Mohammed El-Hadi Shoukat Mohammed Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Other demographic data age, sex, ASA class, co-morbidities during 30 minutes preoperatively
Other duration of surgery in minutes from skin incision up to skin closure
Other weight kilograms during 30 minutes preoperatively
Other height meter during 30 minutes preoperatively
Other body mass index (BMI) weight in kilograms divided by square height in meter uring 30 minutes preoperatively
Primary The duration of analgesic effect in minutes The duration of analgesic effect is indicated by the 1st analgesic requisite after measurement of VAS defined as the time n minutes between finishing the block technique in ESPB group or after administration of nalbuphine in GA-group, and the request of first dose of postoperative analgesics) when VAS is more than 4 during the 1st 8 hours postoperatively
Secondary mean arterial blood pressure changes mean arterial blood pressure will be assessed and measured in mmHg non invasively intraoperative and post extubation in the 1st hour
Secondary Nalbuphine consumption in mg total dose given post operatively up to 1 hour postoperatively
Secondary visual analogue scale (VAS) for assessment of postoperative pain in numbers, normal scale ranges from 0 to 10 with 0 means no pain and 10 means worst pain imaginable. if VAS score exceeded 4/10; this will be considered insufficient analgesia and participant will be given rescue analgesia at 30 minutes, 45 minutes and 60 minutes, 4 hours and 8 hours after surgery
Secondary Block failure rate patient required more than two 5mg doses of nalbuphine in the first hour postoperatively
Secondary Resumption of peristalsis in hours postoperatively up to 48 hours postoperatively
Secondary incidence of adverse effects postoperative nausea and vomiting, urinary retention, hematoma formation, local anesthetic toxicity and need of postoperative ICU or mechanical ventilation postoperative up to 48 hours
Secondary Incidence of shoulder pain percent postoperativey up to 24 hours
Secondary length of hospital stay in days postoperative up to 28 days postoperatively
Secondary heart rate heart rate in beat per minute will be measured intraoperatively and throughout one hour postextubation
Secondary Failure rate of the ESP block the block will be considered a failed block if the patient required more than two 5mg doses of nalbuphine in the first hour postoperatively
See also
  Status Clinical Trial Phase
Completed NCT03657927 - A Comparison of McGrath MAC Versus C-MAC Videolaryngoscopes in Morbidly Obese Patients N/A
Recruiting NCT04934826 - Comparison of the Absorption of Hydrolyzed or Intact Proteins in Morbid Obese Patients After the Roux Y Gastric Bypass N/A
Completed NCT03181347 - The Microbiology of Bariatric Surgery N/A
Completed NCT03886870 - Obesity, Lifestyle and Work Intervention N/A
Active, not recruiting NCT04433338 - The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery N/A
Completed NCT03553849 - Utilization of Very Low Calorie Diet in Obese General Surgery Patients N/A
Completed NCT05854875 - Diabetes Remission After RYGBP and RYGBP With Fundus Resection N/A
Not yet recruiting NCT03203161 - Registry on Obesity Surgery in Adolescents
Not yet recruiting NCT03601273 - Bariatric Embolization Trial for the Obese Nonsurgical Phase 1
Recruiting NCT02129296 - Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study Phase 1/Phase 2
Active, not recruiting NCT01564732 - Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding N/A
Completed NCT02033265 - Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity
Not yet recruiting NCT01652105 - Randomized Trial of Preoperative Diets Before Bariatric Surgery N/A
Completed NCT01963637 - Gastric Volumetry by Gastric Tomodensitometry With Gas N/A
Terminated NCT01759550 - Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
Completed NCT01149512 - Outcomes of the Adjustable Gastric Band in a Publicly Funded Obesity Program N/A
Completed NCT01955993 - Fentanyl Metabolism in Obese Adolescents N/A
Recruiting NCT01685177 - Single Anastomosis Duodeno-Ileal Bypass vs Standard Duodenal Switch as a Second Step After Sleeve Gastrectomy in the Super-Morbid Obese Patient N/A
Completed NCT01536197 - Taste Perception Pre and Post Bariatric Surgery N/A
Completed NCT02929212 - Effect of Number of Meals on Metabolism After Weight Loss Surgery N/A